Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity

Yiqi Ruben Luo[1], Indrani Chakraborty[2], Cassandra Yun[1], Alan H.B. Wu[1], Kara L. Lynch[1]

[1]Department of Laboratory Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, CA, USA

[2]Gator Bio, Palo Alto, CA, USA

Running head: SARS-CoV-2 Antibody Avidity Maturation

Corresponding Author: Yiqi Ruben Luo

Address: Bldg 5 Rm 2M16, 1001 Potrero Ave, San Francisco, CA 94110

Tel: 415-206-8399

Email: ruben.luo@ucsf.edu

Key words: COVID-19; SARS-CoV-2; antibody avidity; label-free immunoassay; diagnosis

Abstract

The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was studied. The IgG avidity assay used a novel label-free immunoassay technology to test IgG against the virus spike protein receptor-binding domain (RBD). The technology, thin-film interferometry (TFI), is able to sense the formation of immune complex on a sensing probe without attaching a reporter (enzyme, fluorophore, etc.). It was found that there was a strong correlation between IgG antibody avidity and days since symptom onset ($p < 0.0001$). In addition, peak readings were significantly higher for specimens from ICU than non-ICU patients for the first month after symptom onset (1-4 weeks) and thereafter ($p<0.0001$). The findings are consistent for what has been reported for SARS-CoV. Given that SARS-CoV-2 specific IgG avidity is strong in ICU patients after 1 month, the antibody-mediated immune enhancement triggered by suboptimal antibodies may not play a role in COVID-19 disease progression and severity.

Main Text

In the race to identify correlates of COVID-19 immunity, the focus has been on characterizing the production of SARS-CoV-2 antibodies. Most immunocompetent individuals with symptomatic infections develop detectable SARS-CoV-2 antibodies within 2 weeks of symptom onset (1). The SARS-CoV-2 IgG antibody response is more robust in severe cases of COVID-19 at all time-points after seroconversion (1). Preliminary findings suggest that the magnitude of the response correlates with virus neutralizing power, but some hypothesize that the antibodies could promote disease progression (2). Influential factors in the distinction between protective antibodies and those that promote pathology include antibody isotype,

concentration, specificity, post-translational modifications, and avidity for the virus. Most SARS-CoV-2 antibody studies to date have focused on the quantity of specific isotypes rather than the quality of the antibodies. Antibody avidity, or functional affinity, is a measure of the maturation of the humoral immune response after both infection and vaccination and typically increases over time. For some viruses, the measurement of antibody avidity is used to differentiate acute infection from past exposure/vaccination (e.g. toxoplasmosis) and to detect re-infection in the presence of prolonged virus-shedding (3). Here we report the development of a method to characterize SARS-CoV-2 IgG avidity maturation in COVID-19 patients from initial diagnosis through convalescence.

Thin-film interferometry (Gator™ Analyzer, Gator Bio, Palo Alto, CA), a label-free immunoassay technology which can measure the time course of formation of an immune complex on a sensing probe without attaching a reporter (4), was used to measure SARS-CoV-2 IgG avidity to the virus spike protein receptor-binding domain (RBD). Individual and serial serum samples (n=168) from patients with PCR-confirmed COVID-19 (n=90, 51% male, median age 49, 24% admitted to the ICU) were diluted 10 fold in running buffer (PBS with 0.05% Tween 20, 0.5% BSA, and 0.05% NaN_3). The steps of the IgG avidity assay included 1) formation of RBD-IgG immune complex on the sensing probe, 2) dissociation of loosely bound IgG (running buffer or 3 M urea in running buffer), and 3) formation of RBD-IgG-Anti-IgG immune complex. The signal increase in the final step was measured and is proportional to the quantity of RBD-IgG-Anti-IgG immune complex on the sensing probe. The IgG avidity index was calculated as the ratio of the readout with the dissociation agent (urea) to the reference (running buffer), presented as a percentage. The study was approved by the Institutional Review

Board of the University of California. All testing was performed on remnant serum samples collected for routine clinical testing and stored at -20°C prior to testing.

Using least squares linear regression analysis, there was a strong correlation between IgG avidity and days since symptom onset ($p < 0.0001$) (Fig. 1A). SARS-CoV-2 IgG avidity did not correlate with IgG concentration, as measured previously using a quantitative immunoassay (1). The kinetics of IgG avidity maturation in 13 patients for whom serial samples ($\geq$3) were available is shown in Fig 1B. In all patients, IgG avidity increased over time. Peak measurements, which included the last measurement per 7-day interval per patient, were used to compare IgG avidity by disease severity. Peak readings were significantly higher for specimens from ICU than non-ICU patients for the first month after symptom onset (1-4 weeks) and thereafter ($p<0.0001$) (Fig. 1C).

To our knowledge this is the first study to evaluate antibody avidity maturation in COVID-19 patients. The findings confirm that IgG avidity significantly increases from 1-90 days post-symptom onset and is significantly associated with disease severity. The findings are consistent for what has been reported for SARS-CoV where avidity indices were low among serum samples collected $\leq$50 days after symptom onset (30.8% $\pm$ 11.6%), intermediate from 51-90 days (52.1% $\pm$ 14.1%), and high for samples collected after 90 days (78.1% $\pm$ 8.0%) (5). The availability of samples after 90 days for SARS-CoV-2 in our cohort was limited at the time of this analysis.

For other viruses, high-avidity antibodies capable of blocking receptor binding typically do not induce disease progression. Given that SARS-CoV-2 specific IgG avidity is strong in ICU patients after 1 month, the antibody-mediated immune enhancement triggered by suboptimal antibodies may not play a role in COVID-19 disease progression and severity. Further studies are

needed to determine if the antibody response, both IgG concentration and avidity, correlate with virus neutralization and persist over time. The avidity method described here makes use of the label-free immunoassay technology, thin-film interferometry, which allows for direct observation of the time course of immune complex formation. This technology could be a valuable tool for continued characterization of the adaptive immune response to SARS-CoV-2.

References

1. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. [Epub ahead of print] Clin Infect Dis July 14, 2020 as doi: 10.1093/cid/ciaa979.
2. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20(5):565-74.
3. Hazell SL. Clinical utility of avidity assays. Expert Opin Med Diagn 2007;1(4):511–9.
4. Luo YR, Chakraborty I, Lazar-Molnar E, Wu AHB, Lynch KL. Development of label-free immunoassays as novel solutions for the measurement of monoclonal antibody drugs and antidrug antibodies. [Epub ahead of print] Clin Chem July 14, 2020 as doi: 10.1093/clinchem/hvaa179.
5. Chan PKS, Lim P, Liu EYM, Cheung JLK, Leung DTM, Sung JJY. Antibody Avidity Maturation during Severe Acute Respiratory Syndrome–Associated Coronavirus Infection. J Infect Dis 2005;192(1):166–9.

Figure Captions

Figure 1. Kinetics of SARS-CoV-2 IgG avidity and distribution of response by level of care (ICU vs non-ICU). (A) Correlation between SARS-CoV-2 IgG avidity and days after symptom onset (n=90 COVID patients, n=168 serum samples). (B) Kinetics of SARS-CoV-2 IgG avidity by days after symptom onset for 13 patients with ≥3 serial samples available for testing. (C) Distribution of IgG avidity by level of care.

Figure 1